Supplementary material

Table S1 Details on how the patient cohorts considered at highest risk from COVID-19 and to be prioritised for treatment with antivirals and nMABs were defined by NHS Digital, and how they were applied in the present study. We include links to the codelists used and describe limitations.

(take	COVID-19 therapeutics high risk cohort identification (taken from https://digital.nhs.uk/coronavirus/treatments/methodology/rule-logic#chapter-index)				Codelists		
Cohort	Description	Data used	Data used Rule logic		Source OpenCodelists link		
Down's syndrome	All patients with down's syndrome	GPES At Risk v4 HES (2006+)	As per Shielded Patient List rules	COVID-19 therapeutics code list and rule set dataset (Down's syndrome tab from COVID+methodology+co horts++.xlsx)	https://www.opencodelists.org/c odelist/nhsd/downs-syndrome-s nomed-ct/3bb246d7/ https://www.opencodelists.org/c odelist/nhsd/downs-syndrome-i cd-10/22a2d3a2/		
	Active metastatic cancer and active solid cancers (at any stage)	Non-digital solution via the oncology units			https://www.opencodelists.org/c odelist/opensafelv/lung-cancer- snomed/2020-04-15/ https://www.opencodelists.org/c odelist/opensafely/cancer-exclu ding-lung-and-haematological-s nomed/2020-04-15/	As non digital solutions were used alongside datasets not available in OpenSAFELY,	
cher	All patients receiving chemotherapy within the last 3 months	SACT classified as category B or C in the Chemotherapy Treatment Benchmark Groups as defined by the updated QCOVID Population Risk Assessment code set within the last 12 months	SACT is 3-6 months in arrears, a non-digital solution will cover the deficit via the oncology units.		https://www.opencodelists.org/c odelist/opensafely/chemotherap y-or-radiotherapy-snomed/2020	patients with a solid cancer were identified using a combination of three OpenSAFELY codelists: 1. Lung Cancer 2. Other Cancers 3. Chemotherapy or Radiotherapy	
	Patients receiving radiotherapy within the last 6 months	RTDS within the last 6 months HES (2006+) within the last 6 months	RTDS is 3-6 months in arrears, HES data identifies 50% 0-6 months. A non-digital solution will cover the deficit via the oncology units.		<u>-04-15/</u>		
Patients with a haematological disease and stem cell transplant recipients	Allogeneic haematopoietic stem cell transplant (HSCT) recipients in the last 12 months or active graft vs host disease (GVHD) regardless of time from transplant Autologous HSCT recipients in the last 12 months (including HSCT for non-malignant diseases)	GPES At Risk v4 HES (2006+) OPCS4	As per Shielded Patient List rules All HSCT transplants are currently included for clinical triage regardless of time from transplant.	3rd primary dose cohort identification specification (ID 5 - Haematological Transplants set)	https://www.opencodelists.org/codelisty/nhsd/haematopoietic-stem-cell-transplant-snomed/3ec3ac16/ https://www.opencodelists.org/codelist/nhsd/haematopoietic-stem-cell-transplant-icd-10/395e2c2a/ https://www.opencodelists.org/codelist/nhsd/haematopoietic-stem-cell-transplant-opcs4/204eb8f5/	Includes non-digital identification so not all patients will be able to be identified. Some of the HES codelist have been removed as they don't exist in ICD-10. These are reflected in the codelists available on opencodelists.org.	

(take	COVID-19 therapeuticn from https://digital.nhs.uk/coronavir	s high risk cohort identifica us/treatments/methodology/ru	С	odelists	Limitations	
Patients with a haematological disease and stem cell transplant	Individuals with haematological malignancies who have • received chimaeric antigen receptor (CAR)-T cell therapy in the last 24 months, or • anti-CD20 monoclonal antibody therapy in the last 12 months • anti-CD38 monoclonal antibody or B-cell maturation agent (BCMA) targeted therapy in the last 6 months	GPES At Risk v4 HES (2006+) OPCS4	Population Risk Assessment (PRA) code clusters. The current cohorting rules limit Haematological malignancies to: • Chronic lymphocytic leukaemia (CLL) • B-cell lymphoma • Follicular lymphoma • Waldenstrom's macroglobulinaemia • Multiple myeloma • Acute lymphoblastic leukaemia • A non-digital solution will cover the deficit via the oncology units There is also a digital cohorting limitation that hospital-only medication is not stored centrally, therefore all the Haematological Malignancies listed above are included for clinical triage, regardless of treatment.	3rd primary dose cohort identification specification (ID 1 - Haematological Cancers set)	https://www.opencodelists.org/c odelist/nhsd/haematological-ma lignancies-snomed/31a49191/ https://www.opencodelists.org/c odelist/nhsd/haematological-ma lignancies-icd-10/073f45c0/	
	Individuals with chronic B-cell lymphoproliferative disorders, receiving systemic treatment or radiotherapy within the last 3 months reduced peripheral B cell counts or hypogammaglobulinem Other B-cell lymphoproliferative disorders	GPES At Risk v4 HES (2006+) OPCS4	Population Risk Assessment (PRA) code clusters All chronic B-cell lymphoproliferative disorders are currently included for clinical triage, regardless of time treatment			
	All patients with sickle cell disease	GPES At Risk v4 HES (2006+)	As per Shielded Patient List rules	COVID-19 therapeutics code list and rule set dataset ('Sickle' tabs from COVID+methodology+c ohorts++.xlsx)	https://www.opencodelists.org /codelist/nhsd/sickle-spl-atrisk v4-snomed-ct/7083ed37/ https://www.opencodelists.org /codelist/nhsd/sickle-spl-hes-i cd-10/789c2d19/	

(takeı	COVID-19 therapeution from https://digital.nhs.uk/coronavir	s high risk cohort identificat us/treatments/methodology/ru		С	odelists	Limitations
Patients with renal disease	Renal transplant recipients (including those with failed transplants within the past 12 months), particularly those who Received B cell depleting therapy within the past 12 months (including alemtuzumab, rituximab Have an additional substantial risk factors Have not been vaccinated prior to transplantation	GPES At Risk v4 HES (2006+) OPCS4	As per Shielded Patient List rules Includes all solid transplant patients for clinical triage, regardless of treatment, risk factors and vaccination status, excluding the SPL rule that restricted identification of patients to those with PCPM immunosuppression medication. Excludes autologous transplants			As the suggested transplant codelists to use here include ALL types of transplants, renal transplant patients will be
	Non-transplant patients who have received a comparable level of immunosuppression	GPES At Risk v4 GDPPR HES (2006+)	Population Risk Assessment (PRA) code clusters for Immunosuppressant drugs. Anyone, regardless of clinical condition, who has had one of these drugs issued within the last 6 months. There is a digital cohorting limitation that hospital-only medication is not stored centrally, therefore there is a non-digital solution for any patients who have had immunosuppressant drugs within the last 6 months that are only hospital prescribed (see section below).			transplant patients will be excluded from this group and included in the solid organ transplant group below. Includes non-digital identification of CKD stage 4. The ICD-10 code for CKD stage 4 seems to meet the inclusion criteria however it is not included in the definition. CKD ICD-10 codes for stages 1-4 are 'excluded' in the criteria. No logic has been included for specific exclusion of ppl with
	Patients with chronic kidney stage (CKD) 4 (an eGFR less than 30 ml/min/1.73m2) without immunosuppression	Non-digital solution				these codes, however they have not been included in the CKD 5 codelist (the inclusion criteria for the eligible cohort).
	Patients with chronic kidney stage (CKD) 5 (an eGFR less than 15 ml/min/1.73m2) without immunosuppression	GPES At Risk v4 HES (2006+) OPCS4	As per Shielded Patient List rules	COVID-19 therapeutics code list and rule set dataset (CKD Stage 5 tab from COVID+methodology+co horts++.xlsx)	https://www.opencodelists.org/c odelist/nhsd/ckd-stage-5-snome d-ct/2808538e/ https://www.opencodelists.org/c odelist/nhsd/ckd-stage-5-icd-10/ 7bad9258/	As a result of all of the above, this group is CKD stage 5 only.

(taker	COVID-19 therapeutics high risk cohort identification (taken from https://digital.nhs.uk/coronavirus/treatments/methodology/rule-logic#chapter-index)				Codelists	
	Patients with cirrhosis Child's-Pugh class B and C (decompensated liver disease). Patients with cirrhosis Child's-Pugh class A who are not on immune suppressive therapy (compensated liver disease)	GPESv4 HES (2006+)	Clinically Extremely Vulnerable (CEV) codes that were identified for SPL implementation	COVID-19 therapeutics	https://www.opencodelists.org/c odelist/nhsd/liver-cirrhosis-icd-1	
	Patients with a liver transplant		As per Shielded Patient List rules Includes all solid transplant patients for clinical triage, excluding the SPL rule that restricted identification of patients to those with PCPM immunosuppression medication. Excludes autologous transplants	dataset (Liver Cirrhosis tab from COVID+methodology+co horts++.xlsx)	0/3e6506cd/ https://www.opencodelists.org/c odelist/nhsd/liver-cirrhosis/64f2 39d0/	As the suggested codelists for "Liver patients on immunosuppressive therapy (including patients with and without liver cirrhosis)" is the same as the one used to identify IMID patients below. Liver disease patients meeting this criteria may therefore end
	Liver patients on immunosuppressive therapy (including patients with and without liver cirrhosis)	GPES At Risk v4 GDPPR HES (2006+)	Population Risk Assessment (PRA) code clusters Immunosuppressant drugs. Anyone, regardless of clinical condition, who has had one of these drugs issued within the last 6 months. There is a digital cohorting limitation that hospital only medication is not stored centrally, therefore there is a non-digital solution for any patients who have had immunosuppressant drugs within the last 6 months that are only hospital prescribed (see section below)			up being included in the IMID cohort and not in the 'Liver disease' cohort. Includes non-digital identification.

(taker	COVID-19 therapeution from https://digital.nhs.uk/coronavi	cs high risk cohort identificat		Codelists		Limitations
Patients with immune-mediated inflammatory disorders (IMID)	IMID with • treated with rituximab or other B cell depleting therapy in the last 12 months • active or unstable disease on corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate. • stable disease on either tacrolimus, cyclosporin or mycophenolate. • active/unstable disease including those on biological monotherapy and on combination biologicals with thiopurine or methotrexate • stable disease on either tacrolimus, cyclophosphamide, cyclosporin or mycophenolate.	GPES At Risk v4 GDPPR HES (2006+)	Population Risk Assessment (PRA) code clusters for Immunosuppressant drugs. Anyone, regardless of clinical condition, who has had one of these drugs issued within the last 6 months. There is a digital cohorting limitation that hospital only medication is not stored centrally, therefore there is a non-digital solution for any patients who have had immunosuppressant drugs within the last 6 months that are only hospital prescribed (see section below)	COVID-19 therapeutics code list and rule set dataset (Immunosuppressant Drugs (PRA) tab from COVID+methodology+co horts++.xlsx)	https://www.opencodelists.org/c odelist/nhsd/immunosuppresant -drugs-pra-dmd/526d9f5f/ https://www.opencodelists.org/c odelist/nhsd/immunosuppresant -drugs-pra-snomed/6b7d1294/	Includes non-digital identification Within the NHSD DM+D codelist for Immunosuppressant drugs, 3 SNOMED codes were identified. These codes are deprecated SNOMED codes and have been put into a separate SNOMED codelist which was used in the study in combination with the DM+D codelist
	IMID with active/unstable disease on corticosteroids IMID with stable disease on corticosteroids IMID with stable disease on corticosteroids IMID with stable disease on corticosteroids	GPES At Risk v4 GDPPR		COVID-19 therapeutics code list and rule set dataset Oral Steroid Drugs (PRA) tab from COVID+methodology+co horts++.xlsx)	https://www.opencodelists.org/c odelist/nhsd/oral-steroid-drugs- pra-dmd/44292c02/ https://www.opencodelists.org/c odelist/nhsd/oral-steroid-drugs- snomed/1ae93909/	Within the NHSD DM+D codelist for <i>Oral Steroid drugs</i> , 1 SNOMED code was identified. This code is a deprecated SNOMED code. The code has been put into a separate the SNOMED codelist which was used in the study in combination with the DM+D codelist

(take	COVID-19 therapeutics high risk cohort identification (taken from https://digital.nhs.uk/coronavirus/treatments/methodology/rule-logic#chapter-index)				Codelists	
Primary immune deficiencies	Common Variable Immunodeficiency (CVID) Undefined primary antibody deficiency on immunoglobulin (or eligible for Ig) Hyper-IgM syndromes Good's syndrome (thymoma plus B-cell deficiency) Severe Combined Immunodeficiency (SCID) Autoimmune polyglandular syndromes/autoimmun e polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome) Primary immunodeficiency associated with impaired type I interferon signalling X-linked agammaglobulinaemia (and other primary agammaglobulinaemia s)	GPES At Risk v4 GDPPR HES (2006+)	Population Risk Assessment (PRA) code clusters There is a digital cohorting limitation in that Autoimmune polyglandular syndromes/autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome) is not included. A non-digital solution will cover the deficit via the specialist units (see section below)	COVID-19 therapeutics code list and rule set dataset (Immunosupression (PCDCluster) tab from COVID+methodology+co horts++.xlsx)	https://www.opencodelists.org/c odelist/nhsd/immunosupression -pcdcluster-snomed-ct/0993606 d/	Includes non-digital identification
HIV/AIDS	Patients with high levels of immune suppression, have uncontrolled/untreated HIV (high viral load) or present acutely with an AIDS defining diagnosis On treatment for HIV with CD4 <350 cells/mm3 and stable on HIV treatment or CD4>350 cells/mm3 and additional risk factors (e.g. age, diabetes, obesity, cardiovascular, liver or renal disease, homeless, those with alcohol-dependence)	GPES At Risk v4 HES (2006+) OPCS4	Population Risk Assessment (PRA) code clusters Includes all people with HIV regardless of CD4 count, viral load and risk factors.	3rd primary dose cohort identification specification (ID 3 - Immunosuppression code set)	https://www.opencodelists.org/c odelist/nhsd/hiv-aids-snomed/6 8ca529e/ https://www.opencodelists.org/c odelist/nhsd/hiv-aids-icd10/01d 9c5d4/	

(take	COVID-19 therapeutics high risk cohort identification (taken from https://digital.nhs.uk/coronavirus/treatments/methodology/rule-logic#chapter-index)				odelists	Limitations
Solid organ transplant recipients	All recipients of solid organ transplants not otherwise specified above	GPES At Risk v4 HES (2006+) OPCS4	Clinically Extremely Vulnerable codes that were identified for SPL implementation	COVID-19 therapeutics code list and rule set dataset (Transplant tabs from COVID+methodology+co horts++.xlsx)	https://www.opencodelists.org/c odelist/nhsd/transplant-spl-atris kv4-snomed-ct/57747a02/ https://www.opencodelists.org/c odelist/nhsd/transplant-spl-hes- opcs4/1b47de52/ https://www.opencodelists.org/c odelist/nhsd/transplant-conjunct iva-spl-hes-opcs4/2dcc78c3/ https://www.opencodelists.org/c odelist/nhsd/transplant-conjunct iva-y-codes-spl-hes-opcs4/14bd 058e/ https://www.opencodelists.org/c odelist/nhsd/transplant-ileum_1- y-codes-spl-hes-opcs4/0113124 5/ https://www.opencodelists.org/c odelist/nhsd/transplant-ileum_1- spl-hes-opcs4/3331f8af/ https://www.opencodelists.org/c odelist/nhsd/transplant-ileum_2- y-codes-spl-hes-opcs4/68039f0f https://www.opencodelists.org/c odelist/nhsd/transplant-ileum_2- spl-hes-opcs4/1a22857a/ https://www.opencodelists.org/c odelist/nhsd/transplant-replace ment-of-organ-spl-hes-opcs4/46 dbebf8/ https://www.opencodelists.org/c odelist/nhsd/transplant-replace ment-of-organ-spl-hes-opcs4/46 dbebf8/ https://www.opencodelists.org/c odelist/nhsd/transplant-stomach -spl-hes-opcs4/6550df19/	The NHS Digital solid organ transplant list covers all transplants (including renal and liver) and ALL transplant patients will be included in this group and not any of the other condition subgroups, as described by NHS Digital. Some HES transplant codes contain 2 codes required to identify transplants. These have been included with logic in the study definition, however for each '2 code' transplant, the component codelists were added to opencodelists. For example; stomach transplant is defined as having G388: 'Other specified open operations on the stomach' + any of the 'replacement of organ' Y codes (for example Y018 'Other specified replacement of organ'). The date of the Y-code, defining the nature of the procedure as a transplant is used as a date restriction in looking for the organ specific code, thus both codes need to be present on the same hospital spell admission date to qualify as a transplant. The code Z94 is described as a transplant specific OPCS code in the NHSD source, however this OPCS code actually describes the laterality of a procedure. This code was removed from the analyses as it led to incorrect over identification, and is assumed to be an error in the published codelist.

(take	COVID-19 therapeutics high risk cohort identification (taken from https://digital.nhs.uk/coronavirus/treatments/methodology/rule-logic#chapter-index)				Codelists	
	Multiple sclerosis				https://www.opencodelists.org/c odelist/nhsd/multiple-sclerosis/4 be2c69b/ https://www.opencodelists.org/c odelist/nhsd/multiple-sclerosis-s nomed-ct/7336ad2d/	
Rare neurological	Motor neurone disease	GPES At Risk v4 GDPPR HES (2006+)	Population Risk Assessment (PRA) code clusters collated by the nMABS clinicians to restrict the data to the 4 disease groups.	COVID-19 therapeutics code list and rule set dataset (Multiple Sclerosis, Motor neurone disease, Myasthenia Gravis and Huntingtons diesease tabs from COVID+methodology+co horts++.xlsx)	https://www.opencodelists.org/c odelist/nhsd/motor-neurone-dis ease-icd-10/4117c6c3/ https://www.opencodelists.org/c odelist/nhsd/motor-neurone-dis ease-snomed-ct/5a2739f8/	
conditions					https://www.opencodelists.org/c odelist/nhsd/myasthenia-gravis/ 32d35366/ https://www.opencodelists.org/c odelist/nhsd/myasthenia-gravis- snomed-ct/0c462063/	
	Huntington's disease				https://www.opencodelists.org/c odelist/nhsd/huntingtons/7e01a d05/ https://www.opencodelists.org/c odelist/nhsd/huntingtons-snome d-ct/25559398/	

Table S2 COVID-19 treatment specific eligibility and exclusion criteria, as per the Interim Clinical Commissioning Policy (published on 28 January 2022, effective from 10 February)⁴ for non-hospitalised COVID-19 patients, and how these were applied in the present study. These criteria were applied to identify potential breaches in guidance for patients who received each type of treatment.

Treatment		Eligibility/Exclusion Criteria	Criteria applied in present study*	
		Clinical judgement deems that an antiviral is the preferred option	Not possible ^{†1}	
	Eligibility	Treatment is commenced within 5 days of symptom onset (extended up to a maximum of 7 days if clinically indicated)	As it was not possible to accurately define symptom onset date, positive SARS-CoV-2 test date was used as a proxy and we used a maximum limit of 5 days.	
Paxlovid	criteria	The patient does NOT have a history of advanced decompensated liver cirrhosis or stage 3-5 chronic kidney disease	Not a member of the renal disease of liver disease group as defined in Table S1.	
		Paxlovid has been deemed safe following guidance from the appropriate specialty team(s)	Not possible ^{†1}	
		Children aged less than 18 years	Age>=18 as of earliest of treatment date or positive SARS-CoV-2 test date.	
	Exclusion criteria	Pregnancy	Not possible ^{†2}	
		The patient is taking any of the contraindicated medications	Not possible ^{†¹}	
	Eliaibility	Clinical judgement deems that an nMAB is the preferred option	Not possible ^{†1}	
Sotrovimab	Eligibility criteria	Treatment is delivered within 5 days of symptom onset (extended up to a maximum of 7 days if clinically indicated)	As it was not possible to accurately define symptom onset date, positive SARS-CoV-2 test date was used as a proxy, setting a maximum of 5 days.	
	Exclusion criteria	Children aged under 12 years	Age>=12 as of earliest of treatment date or positive SARS-CoV-2 tes date.	

Treatment		Eligibility/Exclusion Criteria	Criteria applied in present study*
		Adolescents (aged 12-17) weighing 40kg and under	Age 12-17 as of earliest of treatment date or positive SARS-CoV-2 test date, andL latest available weight>40kg, as recorded on or before treatment date or positive SARS-CoV-2 test date using this SNOMED codelist.
		Clinical judgement deems that an antiviral is the preferred option	Not possible [†]
	Eligibility criteria	Treatment with PF-07321332 (nirmatrelvir) plus ritonavir is contraindicated or not possible	Not possible [†]
Remdesivir		Treatment is commenced within 7 days of symptom onset	As it was not possible to accurately define symptom onset date, positive SARS-CoV-2 test date was used as a proxy, with a limit of 7 days before treatment.
	Exclusion criteria	Children aged under 12 years	Age>=12 as of positive SARS-CoV-2 test date.
		Adolescents (aged 12-17) weighing 40kg and under	Age 12-17 as of earliest of treatment date or positive SARS-CoV-2 test date and ILatest available weight>40kg, as recorded on or before each patient's treatment date or positive SARS-CoV-2 test date using this SNOMED codelist.
	Eligibility	Treatment Paxlovid AND sotrovimab are contraindicated or not possible	Not possible ^{†1}
Molnupiravir	criteria	Treatment is commenced within 5 days of symptom onset (extended up to a maximum of 7 days if clinically indicated)	As it was not possible to accurately define symptom onset date, positive SARS-CoV-2 test date was used as a proxy, with limit 5 days before treatment.
	Exclusion	Children aged less than 18 years	Age>=18 as of earliest of treatment date or positive SARS-CoV-2 test date.
	criteria	Pregnancy	Not possible ^{†2}

^{*} Note: all patients who received treatment were included in the population even if they were not identified as meeting the initial eligibility criteria, as described in Table 1

^{†1} It was not possible to identify any forms of clinical judgement that would have informed treatment options

^{†2} Not currently applied due to limitations and inaccuracies in using pregnancy codes as they are not always well-captured in GP records. Methods are being validated and will be applied in future analyses if appropriate

Figure S1: Time (number of days) between positive SARS-CoV-2 test and treatment for COVID-19, broken down by treatment type.





Figure S2: Time between positive SARS-CoV-2 test and treatment for COVID-19, broken down by high risk cohort



REFERENCES

- Digital, N. H. S. Population health: COVID-19 treatment methodology. NHS Digital https://digital.nhs.uk/coronavirus/treatments/methodology/ (accessed Dec 2021).
- OpenSAFELY documentation- What is a Study Definition? OpenSAFELY https://docs.opensafely.org/study-def/ (accessed Jan 2022).
- 3. study_definition.py. *opensafely/antibody-and-antiviral-deployment* https://github.com/opensafely/antibody-and-antiviral-deployment.
- England, N. H. S. Interim clinical commissioning policy: neutralising monoclonal
 antibodies or antivirals for non-hospitalised patients with COVID-19. NHS England
 https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-polic
 y-neutralising-monoclonal-antibodies-or-antivirals-for-non-hospitalised-patients-with-covi
 d-19/ (accessed Jan 2022).
- 5. OpenCodelists: Pregnancy codes recorded in the 8.5 months before the audit run date. https://www.opencodelists.org/codelist/primis-covid19-vacc-uptake/preg/v1/.